BioCentury | Nov 21, 2020
Finance

Mei readies Antengene to take its next steps to becoming a global biotech

Fresh off its $360 million IPO on the Hong Kong stock exchange, Shanghai’s Antengene is looking to take the next step in its evolution by building out its pipeline and launching its first drug....
BioCentury | Nov 6, 2020
Regulation

Nov. 5 Quick Takes: Setback for bluebird sinks shares; plus Cellectis, CRISPR, REMS, Novocure

bluebird delays sickle cell BLAbluebird bio Inc. (NASDAQ:BLUE) lost $9.72 (17%) to $48.83 Thursday after disclosing its BLA submission to FDA for LentiGlobin to treat sickle cell disease will be delayed to late 2022 from 2H21....
BioCentury | Sep 26, 2020
Product Development

Merck’s myeloid data add support for the emerging target class

The myeloid cell targets that have been generating preclinical attention are moving into the clinical arena, and the first look at data from Merck’s ILT4 program provides an early signal that the strategy...
BioCentury | Sep 25, 2020
Finance

With inaugural fund, Pureos looks to build up Swiss biotech ecosystem

Nearly half of Pureos Bioventures’ first fund, which closed this week at $170 million, could be headed towards Swiss drug developers. The firm began investing its global BB Pureos Bioventures LP fund last year. Pureos...
BioCentury | Sep 23, 2020
Deals

Sept. 22 Quick Takes: Celgene CVR still in play; plus Dr. Reddy’s in Sputnik deal, $30M for Siolta, Amgen-Lilly, BioNTech-Novartis, Genentech-Scenic

Priority Review for bluebird-BMS program could fulfill CVR goalFDA’s review timeline for idecabtagene vicleucel (ide-cel, bb2121) from bluebird bio Inc. (NASDAQ:BLUE) and Bristol Myers Squibb Co. (NYSE:BMY) suggests that an approval decision could come before...
BioCentury | Sep 18, 2020
Finance

Lava’s $83M series C exemplifies evolution of Novo Ventures’ investing

Over the past few years Novo Ventures has been ramping up the pace and size of its biotech investments, with Thursday’s $83 million series C round by γδ T cell engager company Lava the latest...
BioCentury | Sep 9, 2020
Product Development

Networking that fueled COVID-19 response should spill into digital sciences and more, says Genmab’s van de Winkel: a BioCentury audio interview

Jan van de Winkel sees a strong future for data sharing and more master protocol trials, fueled by increasing adoption of digital sciences, as companies turn the collaboration they’ve shown in COVID-19 into longer-term productive...
BioCentury | Sep 5, 2020
Translation in Brief

Matt Disney’s microRNA-targeting angiogenesis compound; Arrakis’ platform to find compounds’ RNA targets; dual target CAR Ts for HIV and more

Scripps microRNA-targeted VEGF-A stimulatorA Scripps Research Institute team led by Matthew Disney has designed a compound that targets a  precursor of miR-377, a direct inhibitor of angiogenesis...
BioCentury | Jul 18, 2020
Translation in Brief

Fate licenses rejection-resistant T cell therapies; plus a marker for anti-PD-1 treatment responsiveness, a cell proliferation control switch and more

Baylor’s engineered T cells designed to avoid immune rejection Baylor College of Medicine has granted Fate Therapeutics Inc. (NASDAQ:FATE) an exclusive license to alloimmune defense receptors, which render allogeneic cell therapies resistant to host immune...
BioCentury | Jun 12, 2020
Finance

June 11 Quick Takes: Biotech swept up in sell-off; plus Simcere, Lantern, Cue Health, C2i, BaseLaunch, Sanofi-Cathay and 4BIO

Biotech tumbles as U.S. indexes plunge Biotech indexes fell along with the broader markets Thursdays in a sell-off sparked by fears of an increase in COVID-19 infections. The NASDAQ Composite, S&P 500 and Dow Jones...
Items per page:
1 - 10 of 800